Literature DB >> 3755648

Management of locoregional recurrent breast cancer.

N A Janjan, M D McNeese, A U Buzdar, E D Montague, M J Oswald.   

Abstract

The influence of radiation and/or chemotherapy on locoregional tumor control and survival in patients treated for recurrent breast cancer after radical or modified radical mastectomy is retrospectively evaluated in 164 patients treated between 1972 and 1983 at the University of Texas M. D. Anderson Hospital. Treatment consisted of radiation alone in 57 patients, chemotherapy alone in 50 patients, and a combination of radiation and chemotherapy in 57 patients. Important differences in the composition of these three groups include a preponderance of postmenopausal women (44% vs. 32%) and more patients with four or more positive axillary nodes at the time of initial mastectomy (32% vs. 18%) in the radiotherapy group. Locoregional control of recurrent cancer was achieved in 65% of patients with radiotherapy compared to 46% of patients with chemotherapy (P = 0.049) and 67% with chemotherapy and radiotherapy. The addition of chemotherapy produced a trend toward improved disease-free survival rates. The two prognostic factors affecting tumor control and survival in this study are the tumor burden of the recurrence and the histologic axillary node status at the time of the initial mastectomy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755648     DOI: 10.1002/1097-0142(19861001)58:7<1552::aid-cncr2820580728>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Progress on ThermoBrachytherapy Surface Applicator for Superficial Tissue Diseases.

Authors:  Kavitha Arunachalam; Oana I Craciunescu; Paolo F Maccarini; Jaime L Schlorff; Edward Markowitz; Paul R Stauffer
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2009-02-12

3.  Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.

Authors:  A Rocchi; S Verma
Journal:  Support Care Cancer       Date:  2006-04-05       Impact factor: 3.603

4.  Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients.

Authors:  E M Mora; S E Singletary; A U Buzdar; D A Johnston
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

Review 5.  Clinical decision-making in early breast cancer.

Authors:  C M Balch; S E Singletary; K I Bland
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

6.  Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.

Authors:  Peng Liubao; Wan Xiaomin; Tan Chongqing; Jon Karnon; Chen Gannong; Li Jianhe; Cui Wei; Luo Xia; Cao Junhua
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Size reduction and radiation pattern shaping of multi-fed DCC slot antennas used in conformal microwave array hyperthermia applicators.

Authors:  Paolo F Maccarini; Kavitha Arunachalam; Carlos D Martins; Paul R Stauffer
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2009-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.